Inomax (Nitric Oxide)

Nitric oxide released from Inomax diffuses into the smooth muscle of pulmonary arteries, activates soluble guanylate cyclase, raises cyclic GMP levels, and causes relaxation of the vascular smooth muscle. This selective pulmonary vasodilation reduces vascular resistance without markedly affecting systemic blood pressure.

The dose of Inomax is individualized and set by the treating physician based on the patient’s age, weight, severity of pulmonary hypertension, and response to therapy. Clinicians adjust the inhaled concentration and duration according to clinical guidelines and monitoring results.

Safety data for Inomax during pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the prescribing clinician.

To order Inomax, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Inomax delivers inhaled nitric oxide, offering rapid and selective pulmonary vasodilation with minimal systemic effects, unlike oral phosphodiesterase‑5 inhibitors or intravenous prostacyclin analogues that have broader systemic actions. Its short half‑life allows precise titration, but it requires specialized delivery equipment.

Inomax cylinders should be stored at ambient temperature, away from direct sunlight and heat sources. Keep them in the original packaging, secure them upright, and ensure proper ventilation. Follow local regulations for medical gas storage and handle cylinders with appropriate protective equipment.

Inomax is administered via an endotracheopulmonary delivery system that introduces the gas into the patient’s airway during mechanical ventilation or spontaneous breathing. The inhaled concentration is continuously monitored, and therapy is adjusted based on pulmonary artery pressure and oxygenation parameters.

The most serious risks include severe hypotension, high‑grade methemoglobinemia, rebound pulmonary hypertension after abrupt discontinuation, and rare allergic reactions. Continuous monitoring of blood pressure, methemoglobin levels, and pulmonary hemodynamics is essential to detect these complications early.

Inomax should be avoided in patients with known hypersensitivity to nitric oxide, severe anemia, significant hemolytic disease, or uncontrolled systemic hypotension. It is also contraindicated in individuals where rapid withdrawal could precipitate rebound pulmonary hypertension without proper weaning protocols.